Brought to you by 
Genoptix plans to acquire Rosetta Genomics for $10mm in cash; transaction later terminated
03 Sep 2020
Executive Summary
Oncology diagnostic lab Genoptix Inc. agreed to acquire all outstanding shares of Nasdaq-traded Israeli genomics company Rosetta Genomics Ltd. (cancer diagnostics).
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Pharmaceuticals
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genoptix plans to acquire Rosetta Genomics for $10mm in cash; transaction later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice